Table 1 Clinical characteristics of reports with deutetrabenazine from the FAERS database
Characteristics | Case number | Proportion (%) |
|---|---|---|
Number of events | 4337 | |
Gender (%) | ||
 Female | 2622 | 60.5 |
 Male | 1261 | 29.1 |
 Not specified | 454 | 10.5 |
Weight (kg) | ||
 < 50 | 14 | 0.3 |
 > 100 | 44 | 1.0 |
 50∼100 | 222 | 5.1 |
 Not specified | 4057 | 93.5 |
Age(years) | ||
 < 18 | 24 | 0.6 |
 18∼65 | 1245 | 28.7 |
 65∼85 | 963 | 22.2 |
 >85 | 41 | 0.9 |
 Not specified | 2064 | 47.6 |
Reported Countries | ||
 United States | 4305 | 99.3 |
 Israel | 9 | 0.2 |
 China | 9 | 0.2 |
 Brazil | 3 | 0.1 |
 Puerto Rico | 3 | 0.1 |
 Others | 8 | 0.1 |
Reporter | ||
 Consumer | 2329 | 53.7 |
 Health Professional | 694 | 16.0 |
 Pharmacist | 535 | 12.3 |
 Medical Doctor | 391 | 9.0 |
 Other health-professional | 186 | 4.3 |
 Not specified | 202 | 4.7 |
Year of report | ||
 2017 | 48 | 1.1 |
 2018 | 357 | 8.2 |
 2019 | 590 | 13.6 |
 2020 | 645 | 14.9 |
 2021 | 787 | 18.1 |
 2022 | 496 | 11.5 |
 2023 | 498 | 11.5 |
 2024 | 916 | 21.1 |
Outcomes | ||
 Other serious outcome | 853 | 19.7 |
 Hospitalization | 473 | 10.9 |
 Death | 271 | 6.2 |
 Disability | 23 | 0.5 |
 Required Intervention to Prevent Permanent Impairment | 7 | 0.2 |
 Life-Threatening | 12 | 0.3 |
 Cancer | 2 | 0.1 |
 Not specified | 2696 | 62.1 |
Indications | ||
 Tardive Dyskinesia | 1749 | 40.3 |
 Huntington’s Disease | 537 | 12.4 |
 Dyskinesia | 406 | 9.4 |
 Chorea | 49 | 1.1 |
 Not specified | 1596 | 46.8 |